Longeveron Inc
NASDAQ:LGVN
Longeveron Inc
Cash from Financing Activities
Longeveron Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Longeveron Inc
NASDAQ:LGVN
|
Cash from Financing Activities
$5.3m
|
CAGR 3-Years
49%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Longeveron Inc's Cash from Financing Activities?
Cash from Financing Activities
5.3m
USD
Based on the financial report for Dec 31, 2023, Longeveron Inc's Cash from Financing Activities amounts to 5.3m USD.
What is Longeveron Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
31%
The average annual Cash from Financing Activities growth rates for Longeveron Inc have been 49% over the past three years , 31% over the past five years .